Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Completes Tender Offer for Iris

NEW YORK (GenomeWeb News) – Danaher today said that it has completed its $19.50-per-share offer to acquire Iris International.

The $338 million deal was signed by the firms in September. The purchase price represented a 45 percent premium to Iris' closing stock price of $13.42 on Sept. 14, the day before the agreement was announced.

The tender offer expired yesterday at 5:00 p.m. EDT. As of the expiration of the offer, 16,626,491 shares of Iris had been tendered and not withdrawn, representing nearly 92 percent of Iris's outstanding stock.

Chatsworth, Calif.-based Iris has three operating units: Iris Diagnostics, Iris Sample Processing, and Iris Molecular Diagnostics. The firm also operates a personalized medicine subsidiary developing assays based on the firm's Nucleic Acid Detection Immuno-Assay (NADiA) technology, which combines the specificity of monoclonal antibody capture with the sensitivity of real-time polymerase chain reaction detection. It also operates a CLIA lab and offers a test for identifying patients at risk of developing prostate cancer following a prostatectomy.

Iris will operate as a wholly owned subsidiary of Danaher.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.